Posted by Michael Wonder on 15 Apr 2021
FDA wants more data on promising ALS drug, frustrating patients seeking faster access
15 April 2020 - People living with amyotrophic lateral sclerosis, or ALS, in the U.S. will have to wait longer than their counterparts in Europe and Canada for access to a potentially beneficial treatment, even though the medicine is being developed here.
Patient advocates have responded by accusing the FDA of ignoring the desperate needs of people with ALS and reneging on commitments to speed the approval of new medicines to treat the fatal, neuro-degenerative disease.
